Literature DB >> 8884162

Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').

U D McCann1, S O Slate, G A Ricaurte.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA; 'ecstasy') is an increasingly popular recreational drug in the US, Western Europe and Australia. In animals, including nonhuman primates, MDMA is known to damage brain serotonin (5-hydroxytryptamine; 5-HT) neurons. It is not known whether MDMA damages serotonin neurons in the human brain but there is some indication that it may. Although the large majority of individuals who have used MDMA recreationally do not develop acute complications, as the popularity of MDMA has increased, so have reports of adverse nonpsychiatric and psychiatric consequences associated with use of the drug. Further, since manifestations of MDMA-induced serotonin injury might only become apparent with age, or under periods of stress, it is possible that some individuals with no apparent abnormalities might develop complications over time.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884162     DOI: 10.2165/00002018-199615020-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  80 in total

1.  MDMA (Ecstasy) precipitation of panic disorder.

Authors:  S Pallanti; D Mazzi
Journal:  Biol Psychiatry       Date:  1992-07-01       Impact factor: 13.382

2.  Psychiatric complications of 'Ecstasy' use.

Authors:  H Series; S Boeles; E Dorkins; R Peveler
Journal:  J Psychopharmacol       Date:  1994-01       Impact factor: 4.153

3.  Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.

Authors:  W Slikker; R R Holson; S F Ali; M G Kolta; M G Paule; A C Scallet; D E McMillan; J R Bailey; J S Hong; F M Scalzo
Journal:  Neurotoxicology       Date:  1989       Impact factor: 4.294

4.  Survival following intentional massive overdose of 'Ecstasy'.

Authors:  L Roberts; H Wright
Journal:  J Accid Emerg Med       Date:  1994-03

5.  Cerebral venous sinus thrombosis induced by 'ecstasy'.

Authors:  P M Rothwell; R Grant
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

6.  Ecstasy induced hepatitis mimicking viral hepatitis.

Authors:  R S Dykhuizen; P W Brunt; P Atkinson; J G Simpson; C C Smith
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

7.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

8.  Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine.

Authors:  M A Wilson; G A Ricaurte; M E Molliver
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

9.  "Ecstasy" and sudden cardiac death.

Authors:  R V Suarez; R Riemersma
Journal:  Am J Forensic Med Pathol       Date:  1988-12       Impact factor: 0.921

10.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.

Authors:  D M Stone; D C Stahl; G R Hanson; J W Gibb
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

View more
  15 in total

Review 1.  Ten years of 'ecstasy'.

Authors:  C M Milroy
Journal:  J R Soc Med       Date:  1999-02       Impact factor: 5.344

2.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

3.  Direct influence of serotonin on the larval heart of Drosophila melanogaster.

Authors:  Sameera Dasari; Robin L Cooper
Journal:  J Comp Physiol B       Date:  2005-12-14       Impact factor: 2.200

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 5.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

7.  Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA.

Authors:  A Richard Green; Veronica Sanchez; Esther O'Shea; Kathryn S Saadat; J Martin Elliott; M Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

8.  Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors.

Authors:  Sotiria Bexis; James R Docherty
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 9.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

10.  Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use.

Authors:  Eugene A Kiyatkin; Albert H Kim; Ken T Wakabayashi; Michael H Baumann; Yavin Shaham
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.